1 July 2023 pathology MBS changes

This page provides information on the 1 July 2023 changes to MBS pathology items.

Page last updated: 27 June 2023

Effective 1 July 2023, the following new and amended pathology items will be listed on the MBS:

  • One new item for somatic gene panel testing for the diagnosis and classification of gliomas.
  • Two new items and one amended item for single gene testing for neuromuscular disorders.
  • One new item for antimicrobial drug susceptibility testing for Mycobacterium tuberculosis complex.
  • One administrative amendment to item 73812 for quantitation of glycated haemoglobin (HbA1c) point of care testing.

Further information can be found in the factsheets below:

Fact Sheet
PDF and Word versions
Somatic gene panel testing for the diagnosis and classification of gliomasWord Version Factsheet - Somatic gene panel testing for the diagnosis and classification of gliomas (Word 126 KB)
PDF Version Factsheet - Somatic gene panel testing for the diagnosis and classification of gliomas (PDF 180 KB)
Single gene testing for neuromuscular disordersWord Version Factsheet - Single gene testing for neuromuscular disorders (Word 125 KB)
PDF Version Factsheet - Single gene testing for neuromuscular disorders (PDF 183 KB)
Antimicrobial drug susceptibility testing for Mycobacterium tuberculosis complexWord Version Factsheet - Antimicrobial drug susceptibility testing for Mycobacterium tuberculosis complex (Word 206 KB)
PDF Version Factsheet - Antimicrobial drug susceptibility testing for Mycobacterium tuberculosis complex (PDF 168 KB)
Administrative amendment to item 73812Word Version Factsheet - Administrative amendment to item 73812 (Word 118 KB)
PDF Version Factsheet - Administrative amendment to item 73812 (PDF 149 KB)

In this section